Connect with us

Technology

Vietnam’s Skills In AI Help Precision Medicine Companies

Published

on

Vietnam's Skills In AI Help Precision Medicine Companies

Investments in health technology, particularly in precision medicine, are benefiting from Vietnam’s quick advances in artificial intelligence and technology.

According to DealStreetAsia’s Data Vantage’s “SE Asia Deal Review: Q4 2023” report, health tech investments in Southeast Asia remained up despite the general pessimism surrounding fundraising in 2023. The sector’s startups raised $580 million from 60 agreements. Vietnam was in third place in the area with 3.9% of the investments, while firms in far larger economies like Singapore and Indonesia took home the majority of the funding for health tech.

According to analysts, there has been a surge in interest in Vietnam’s health tech sector in recent times, as there is optimism that the utilization of artificial intelligence can accelerate advancements like precision medicine.

“Vietnam has numerous promising companies in this sector, the market is still at an early stage,” said Vy Le, co-founder and general partner of the venture capital firm Do Ventures.

Precision medicine, also referred to as “personalized medicine,” creates individualized treatments for conditions like cancer, diabetes, or Alzheimer’s by using a patient’s genetic profile. Put another way, a personalized strategy based on the patient’s DNA replaces the typical one-size-fits-all approach to diagnosis and therapy. The promise of AI in this area is that people will be able to affordably sequence their genomes.

Gene Solutions is one of the precision medicine firms in Vietnam that has drawn venture capital. In its Series B funding round, the business brought in $21 million last year. According to the Data Vantage analysis, the transaction, which was led by Mekong Capital, ranked as the seventh-largest health tech deal in Southeast Asia in 2023. Mekong Capital made a $15 million investment in Gene Solutions in 2021.

DealStreetAsia revealed in September 2023 that Gene Solutions is aiming to raise $50 million in a Series C investment.

Established in 2017, Gene Solutions focuses on using DNA markers to identify the existence of specific diseases. It has aided in the detection of chromosomal abnormalities in expectant mothers, averting genetic issues, and assisting with in-vitro fertilization. It seeks to lower the cost of genetic testing and increase accessibility.

One of Gene Solutions’ competitive advantages, according to Chris Freund, founder and partner of Mekong Capital, is “how fast-moving” company. For instance, when we first invested, it was just an idea to grow outside of Vietnam. However, in the last two years, they have successfully partnered with top hospital groups and cancer institutes in [the] Philippines, Malaysia, Indonesia, Thailand, and Singapore, with partial support from a Singaporean lab.

Gene Solutions has completed more than 350,000 genetic tests in the previous five years.

GeneStory is another company in the field; Vingroup founded it in 2022 with a charter capital of 102.3 billion dong ($4.4 million). GeneStory seeks to offer “fast and comprehensive genetic testing services based on a large Vietnamese dataset, exclusively for Vietnamese people.” But in 2022, the conglomerate itself sold a confidential interest in GeneStory. In order to develop individualized health care programs, the startup provides assessments of people’s medical, physical, and dietary risks as well as hereditary characteristics.

Vietnamese venture-backed precision medicine businesses also include Genetica Company, which uses artificial intelligence (AI) to decipher DNA. The 2018-founded company received $2.5 million from Silicon Valley investors in a pre-Series A investment round in 2021.

Genetica has introduced a gene-decoding device that employs artificial intelligence (AI) to determine a person’s genetic susceptibility to respiratory virus infection.

Southeast Asia is seeing a boom in genomic research and development at the same time as interest in precision medicine. The “Harnessing Genomic Medicine and Gene NFT in Southeast Asia” report by DealStreetAsia and Genetica, published in August 2023, states that the region’s unique and diverse genetic makeup is being highlighted through the development of genomic datasets driven by both private-sector initiatives and government-supported programs.

AI has been used in healthcare for a longer period of time than in many other industries, according to Yinglan Tan, CEO and founding managing partner of Insignia Ventures Partners. Applications of AI in healthcare include risk assessment, predictive analytics, and medical imaging. He emphasized that the Asia-Pacific area, particularly Southeast Asia, presents substantial growth potential, holding a 13% share of the worldwide AI health care market.

The increasing need for individualized health care solutions is one of the main factors driving funding for precision medicine firms. Customers are looking for specialized medical solutions as they grow more health-conscious.

“As the tests become even more precise over the coming years, it will enable Gene Solutions to detect diseases with increasingly smaller DNA segments. The cost of those tests will also come down. Eventually, such tests will be affordable for the mass market in Vietnam and Southeast Asia,” said Freund of Mekong Capital.

Through a number of programs and incentives, the Vietnamese government has also been instrumental in supporting the development of precision medicine firms. With the help of the government, a favorable atmosphere for entrepreneurs has been established, drawing both domestic and foreign investors to the emerging health technology market.

Investors are conscious of the constraints, too, such as the fact that the regulatory environment for health IT businesses is still developing. “Investing in biotech companies is typically challenging for VC funds in Vietnam. This industry demands specialized funds with experts in the field,”, according to Vy Le of Do Ventures.

In addition, venture capital funds usually have an investment horizon of four to five years, but the biotech sector needs more time to succeed. This implies that additional government funding is needed. Le gave the example of South Korea, where the government runs a fund specifically intended to invest in biotech investments at different phases of development.

However, new trends in fundraising give the industry hope.

The “The State of Healthtech in SE Asia 2023” DealStreetAsia Data Vantage report discovered that from January 2020 to September 2023, 46% of the region’s health tech startups’ total deal volume and 72% of their equity funding came from investments in deep tech fields related to health care, such as genomics, molecular biology, artificial intelligence, and biometric sensing.

Technology

OpenAI Launches SearchGPT, a Search Engine Driven by AI

Published

on

The highly anticipated launch of SearchGPT, an AI-powered search engine that provides real-time access to information on the internet, by OpenAI is being made public.

“What are you looking for?” appears in a huge text box at the top of the search engine. However, SearchGPT attempts to arrange and make sense of the links rather than just providing a bare list of them. In one instance from OpenAI, the search engine provides a synopsis of its discoveries regarding music festivals, accompanied by succinct summaries of the events and an attribution link.

Another example describes when to plant tomatoes before decomposing them into their individual types. You can click the sidebar to access more pertinent resources or pose follow-up questions once the results are displayed.

At present, SearchGPT is merely a “prototype.” According to OpenAI spokesman Kayla Wood, the service, which is powered by the GPT-4 family of models, will initially only be available to 10,000 test users. According to Wood, OpenAI uses direct content feeds and collaborates with outside partners to provide its search results. Eventually, the search functions should be integrated right into ChatGPT.

It’s the beginning of what may grow to be a significant challenge to Google, which has hurriedly integrated AI capabilities into its search engine out of concern that customers might swarm to rival firms that provide the tools first. Additionally, it places OpenAI more squarely against Perplexity, a business that markets itself as an AI “answer” engine. Publishers have recently accused Perplexity of outright copying their work through an AI summary tool.

OpenAI claims to be adopting a notably different strategy, suggesting that it has noticed the backlash. The business highlighted in a blog post that SearchGPT was created in cooperation with a number of news partners, including businesses such as Vox Media, the parent company of The Verge, and the owners of The Wall Street Journal and The Associated Press. “News partners gave valuable feedback, and we continue to seek their input,” says Wood.

According to the business, publishers would be able to “manage how they appear in OpenAI search features.” They still appear in search results, even if they choose not to have their content utilized to train OpenAI’s algorithms.

According to OpenAI’s blog post, “SearchGPT is designed to help users connect with publishers by prominently citing and linking to them in searches.” “Responses have clear, in-line, named attribution and links so users know where information is coming from and can quickly engage with even more results in a sidebar with source links.”

OpenAI gains from releasing its search engine in prototype form in several ways. Additionally, it’s possible to miscredit sources or even plagiarize entire articles, as Perplexity was said to have done.

There have been rumblings about this new product for several months now; in February, The Information reported on its development, and in May, Bloomberg reported even more. A new website that OpenAI has been developing that made reference to the transfer was also seen by certain X users.

ChatGPT has been gradually getting closer to the real-time web, thanks to OpenAI. The AI model was months old when GPT-3.5 was released. OpenAI introduced Browse with Bing, a method of internet browsing for ChatGPT, last September; yet, it seems far less sophisticated than SearchGPT.

OpenAI’s quick progress has brought millions of users to ChatGPT, but the company’s expenses are mounting. According to a story published in The Information this week, OpenAI’s expenses for AI training and inference might total $7 billion this year. Compute costs will also increase due to the millions of people using ChatGPT’s free edition. When SearchGPT first launches, it will be available for free. However, as of right now, it doesn’t seem to have any advertisements, so the company will need to find a way to make money soon.

Continue Reading

Technology

Google Revokes its Intentions to stop Accepting Cookies from Marketers

Published

on

Following years of delay, Google has announced that it will no longer allow advertisers to remove and replace third-party cookies from its Chrome web browser.

Cookies are text files that websites upload to a user’s browser so they can follow them around when they visit other websites. A large portion of the digital advertising ecosystem has been powered by this practice, which makes it possible to track people across many websites in order to target ads.

Google stated in 2020 that it would stop supporting certain cookies by the beginning of 2022 after determining how to meet the demands of users, publishers, and advertisers and developing solutions to make workarounds easier.

In order to do this, Google started the “Privacy Sandbox” project in an effort to find a way to safeguard user privacy while allowing material to be freely accessible on the public internet.

In January, Google declared that it was “extremely confident” in the advancement of its plans to replace cookies. One such proposal was “Federated Learning of Cohorts,” which would essentially group individuals based on similar browsing habits; thus, only “cohort IDs”—rather than individual user IDs—would be used to target them.

However, Google extended the deadline in June 2021 to allow the digital advertising sector more time to finalize strategies for better targeted ads that respect user privacy. Then, in 2022, the firm stated that feedback had indicated that advertisers required further time to make the switch to Google’s cookie replacement because some had resisted, arguing that it would have a major negative influence on their companies.

The business announced in a blog post on Monday that it has received input from regulators and advertisers, which has influenced its most recent decision to abandon its intention to remove third-party cookies from its browser.

According to the firm, testing revealed that the change would affect publishers, advertisers, and pretty much everyone involved in internet advertising and would require “significant work by many participants.”

Anthony Chavez, vice president of Privacy Sandbox, commented, “Instead of deprecating third-party cookies, we would introduce a new experience in Chrome that lets people make an informed choice that applies across their web browsing, and they’d be able to adjust that choice at any time.” “We’re discussing this new path with regulators and will engage with the industry as we roll it out.”

Continue Reading

Technology

 Samsung Galaxy Buds 3 Pro Launch Postponed Because of Problems with Quality Control

Published

on

At its Unpacked presentation on July 10, Samsung also debuted its newest flagship buds, the Galaxy Buds 3 Pro, with the Galaxy Z Fold 6, Flip 6, and the Galaxy Watch 7. Similar to its other products, the firm immediately began taking preorders for the earphones following the event, and on July 26th, they will go on sale at retail. But the Korean behemoth was forced to postpone the release of the Galaxy Buds 3 Pro and delay preorder delivery due to quality control concerns.

The Galaxy Buds 3 Pro went on sale earlier this week in South Korea, Samsung’s home market, in contrast to the rest of the world. However, allegations of problems with quality control quickly surfaced. These included loose case hinges, earbud joints that did not sit flush, blue dye blotches, scratches or scuffs on the case cover, and so on. It appears that the issues are exclusive to the white Buds 3 Pro; the silver devices are working fine.

Samsung reportedly sent out an email to stop selling Galaxy Buds 3 Pros, according to a Reddit user. These problems appear to be a result of Samsung’s inadequate quality control inspections. Numerous user complaints can also be found on its Korean community forum, where one consumer claims that the firm would enhance quality control and reintroduce the earphones on July 24.

 A Samsung official stated. “There have been reports relating to a limited number of early production Galaxy Buds 3 Pro devices. We are taking this matter very seriously and remain committed to meeting the highest quality standards of our products. We are urgently assessing and enhancing our quality control processes.”

“To ensure all products meet our quality standards, we have temporarily suspended deliveries of Galaxy Buds 3 Pro devices to distribution channels to conduct a full quality control evaluation before shipments to consumers take place. We sincerely apologize for any inconvenience this may cause.”

Should Korean customers encounter problems with their Buds 3 Pro devices after they have already received them, they should bring them to the closest service center for a replacement.

Possible postponement of the US debut of the Galaxy Buds 3 Pro

Samsung seems to have rescheduled the launch date and (some) presale deliveries of the Galaxy Buds 3 Pro in the US and other markets by one month. Inspect your earbuds carefully upon delivery to make sure there are no issues with quality control, especially if your order is still scheduled for July.

The Buds 3 Pro is currently scheduled for delivery in late August, one month after its launch date, on the company’s US store. Additionally, Best Buy no longer takes preorders for the earphones, and Amazon no longer lists them for sale.

There are no quality control difficulties affecting the Buds 3, and they are still scheduled for delivery by July 24, the day of launch. Customers of the original Galaxy Buds 3 Pro have reported that taking them out is easy to tear the ear tips. Samsung’s delay, though, doesn’t seem to be related to that issue.

Continue Reading

Trending

error: Content is protected !!